re-analysis of resonate-2 trial of ibrutinib vs chlorambucil in cll
Published 7 years ago • 172 plays • Length 1:08Download video MP4
Download video MP3
Similar videos
-
1:28
overview of resonate-2 clinical trial of ibrutinib in cll
-
2:56
resonate-2: ibrutinib and chlorambucil for frontline cll
-
1:26
overview of the resonate-2 clinical trial of ibrutinib as front-line therapy
-
1:14
overview of the clinical trial of ibrutinib vs chlorambucil as front-line therapy
-
7:37
resonate, resonate-2 and helios: three major clinical trials in cll research
-
0:49
overview of the cll2-big trial of ibrutinib and obinutuzumab
-
2:45
the value of axi-cel as a second-line treatment in r/r lbcl
-
3:02
the recent withdrawal of voxelotor from the market: the potential impact on patients with scd
-
2:46
a phase ii trial of pembrolizumab for richter's transformation of cll
-
2:07
vitamin d supplementation for early-stage cll is associated with prolonged ttft and tfi
-
4:02
testing for bcr::abl kinase mutations in cml and how they impact tki resistance
-
2:58
results of a phase ib study of ibrutinib obinutuzumab in r/r cll
-
1:37
causes & management of ibrutinib discontinuation in cll
-
1:13
monitoring patients with cll on ibrutinib-based therapies
-
5:56
late-breaking abstract: resonate 2 finds first-line ibrutinib superior to chlorambucil in cll/sll
-
5:40
recommendations for biomarker analysis in cll: updates from eric 2024
-
5:52
understanding ultra high-risk cll and advances with ibrutinib therapy
-
3:14
impressive results from phase 3 resonate trial in cll
-
1:53
clinical outcomes of btki ven treatment in cll/sll: double-exposed vs double-refractory patients
-
1:13
exciting updates in cll: advancing treatment for patients with double-refractory disease
-
1:01
an update on the phase i trial of bms-986393, a novel gprc5d-targeted car-t, in r/r myeloma
-
0:49
overview of the cll2-big trial